Wakino Shu, Hayashi Koichi, Kanda Takeshi, Tatematsu Satoru, Homma Koichiro, Yoshioka Kyoko, Takamatsu Ichiro, Saruta Takao
Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Circ Res. 2004 Sep 3;95(5):e45-55. doi: 10.1161/01.RES.0000142313.68389.92. Epub 2004 Aug 12.
Although peroxisome proliferator-activated receptor gamma (PPARgamma) ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells (RASMC), Rho kinase stimulated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone, and these effects were explained by the inhibition of the Rho translocation to the cell membrane. We evaluated the role of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2), a protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. Furthermore, 4-week treatment with pioglitazone lowered systolic blood pressure in spontaneously hypertensive rats (SHR) and suppressed the Rho/Rho kinase activity in aortic tissues isolated from SHR. Consistently, the expression of SHP-2 was upregulated in vascular tissues from pioglitazone-treated SHR. The phosphorylated Vav was increased in SHR, compared with that in normotensive Wistar-Kyoto rats (WKY), which was mitigated by pioglitazone. Finally, both basal and angiotensin II-stimulated levels of Rho kinase activity were greater in RASMC from SHR than those from WKY, and the enhanced Rho kinase activity was blocked by pioglitazone or troglitazone in both strains. Collectively, PPARgamma ligands inhibit the Rho/Rho kinase pathway through upregulation of cytosolic SHP-2 expression and inactivation of Vav, and may contribute to the hemodynamic, in addition to metabolic, action in hypertensive metabolic syndrome. The full text of this article is available online at http://circres.ahajournals.org.
尽管过氧化物酶体增殖物激活受体γ(PPARγ)配体在体内具有降压作用,但其确切机制尚未完全阐明。我们研究了它们对Rho/Rho激酶途径的影响,该途径是血管张力的关键调节因子。在培养的大鼠主动脉平滑肌细胞(RASMC)中,吡格列酮和曲格列酮预处理可抑制血管紧张素II刺激的Rho激酶,这些作用可通过抑制Rho向细胞膜的转位来解释。我们评估了Vav(一种上调Rho激酶活性的鸟苷三磷酸/鸟苷二磷酸交换因子)和含Src同源区2的蛋白酪氨酸磷酸酶-2(SHP-2,一种使Vav去磷酸化并随后使Rho激酶失活的蛋白酪氨酸磷酸酶)的作用。吡格列酮和曲格列酮均上调SHP-2,特别是在胞质部分,以及与SHP-2结合的Vav,并降低Vav的磷酸化。此外,吡格列酮4周治疗可降低自发性高血压大鼠(SHR)的收缩压,并抑制从SHR分离的主动脉组织中的Rho/Rho激酶活性。一致地,吡格列酮治疗的SHR血管组织中SHP-2的表达上调。与正常血压的Wistar-Kyoto大鼠(WKY)相比,SHR中磷酸化的Vav增加,吡格列酮可减轻这种增加。最后,SHR的RASMC中基础和血管紧张素II刺激的Rho激酶活性水平均高于WKY的,并且两种品系中增强的Rho激酶活性均被吡格列酮或曲格列酮阻断。总体而言,PPARγ配体通过上调胞质SHP-2表达和使Vav失活来抑制Rho/Rho激酶途径,并且除了代谢作用外,可能还对高血压代谢综合征的血流动力学作用有贡献。本文全文可在http://circres.ahajournals.org在线获取。